OncLive Insights

Panelists discuss how evolving molecular classification, improved detection methods, and emerging data from novel tyrosine kinase inhibitors like firmonertinib are transforming the treatment of non–small cell lung cancer (NSCLC) with EGFR PACC mutations. They highlight a future where advanced sequencing and innovative therapeutic strategies will enable more precise, effective, and durable management of this complex molecular subset.

Panelists discuss the role of biomarker testing, when it should be performed, and how comprehensive profiling can shape individualized care. Panelists discuss the evolving treatment landscape for FGFR2b-positive gastric cancer, highlighting key ongoing and late-phase trials as well as future approvals on the horizon. Panelists discuss how biomarker-driven decision-making guides therapy selection, considering how molecular findings, clinical characteristics, and emerging data influence both first-line and subsequent treatment strategies.

Panelists discuss evolving first- and second-line treatment strategies for extensive-stage small cell lung cancer, emphasizing evidence-based integration of immunotherapy, personalized maintenance approaches, toxicity management, and the promise of emerging targeted and immune-based therapies to improve survival and quality of life.

Panelists discuss the rapidly evolving frontline management of advanced renal cell carcinoma, highlighting progress in combination immunotherapy, precision-based treatment, toxicity management, and the promise of emerging therapies that are reshaping the standard of care.

Panelists discuss how innovative treatment strategies, including immune-based and cell-directed therapies, are transforming care for patients with relapsed or refractory follicular and marginal zone lymphomas by improving long-term outcomes, enhancing safety, and prioritizing patient-centered approaches that balance efficacy, quality of life, and access to advanced, personalized treatment options.

Panelists discuss how patients with unresectable hepatocellular carcinoma present with dual challenges of managing both the cancer and underlying cirrhotic liver disease, emphasizing the complexity of applying clinical trial data from patients with Child-Pugh A status to the more heterogeneous Child-Pugh B population commonly seen in practice.

Panelists discuss how intravenous administration of immune checkpoint inhibitors creates operational challenges, including infusion chair bottlenecks, complex scheduling, venous access difficulties, and time burdens for patients, while subcutaneous formulations offer potential solutions through simplified delivery, reduced infusion center strain, and improved patient convenience.

Panelists discuss how recent FDA-approved therapies for chronic graft-vs-host disease (GVHD; ibrutinib, ruxolitinib, belumosudil, and axatilimab) have transformed treatment approaches by enabling earlier intervention after steroid failure, targeting distinct immunological pathways, and improving patient outcomes through personalized treatment sequencing based on organ involvement, toxicity profiles, and practical considerations like oral vs intravenous administration.

Panelists discuss how CAR T-cell therapy has evolved from a highly toxic inpatient treatment to a safer, increasingly accessible therapy that can often be administered on an outpatient basis, with improved patient outcomes when referred early in the treatment journey and enhanced collaboration between academic centers and community oncologists for optimal patient care.

Komal Jhaveri, MD, FACP; and Kevin M. Kalinsky, MD, MS, discuss how emerging oral selective estrogen receptor degraders and proteolysis-targeting chimeras are transforming breast cancer treatment by providing new targeted options for ESR1-mutant tumors, the evolving role of CDK4/6 inhibitor sequencing strategies including molecular progression–based treatment switching, and the integration of antibody-drug conjugates across different breast cancer subtypes from later-line to first-line metastatic settings.

Panelists discuss how HER2 mutations in metastatic non–small cell lung cancer (mNSCLC) require comprehensive molecular testing including both next-generation sequencing and immunohistochemistry, and how the recent FDA approval of zongertinib as a HER2-specific tyrosine kinase inhibitor provides a new targeted therapy option with superior tolerability compared with trastuzumab deruxtecan, emphasizing the importance of proper treatment sequencing and the evolving landscape from chemotherapy-based approaches to precision medicine in this patient population.

Panelists explore treatment strategies and the integral role of the multidisciplinary care team in optimizing outcomes in CML.

Experts discuss the evolving treatment landscape of pediatric low-grade glioma (pLGG), including molecular testing, frontline and relapsed therapy strategies, multidisciplinary decision-making, and real-world case applications to optimize personalized care.

John Allan, MD; Susan O’Brien, MD; and Javier Pinilla, MD, PhD, discuss how shared decision-making in chronic lymphocytic leukemia (CLL) treatment involves balancing Bruton tyrosine kinase (BTK) inhibitor safety profiles, efficacy data, and patient preferences when choosing among continuous monotherapy, fixed-duration combinations, and managing treatment-related adverse events through dose modifications and multidisciplinary care approaches.

Peter Voorhees, MD and Louis Williams, MD discuss how CAR T-cell therapy eligibility assessment, optimal timing for earlier-line treatment, long-term efficacy data from CARTITUDE studies, and emerging next-generation CAR T products are reshaping the treatment landscape for relapsed/refractory multiple myeloma patients.

Julia Foldi, MD, PhD; Elisa Krill-Jackson, MD; and Timothy J. Pluard, MD, discuss how the INAVO120 trial’s final overall survival (OS) analysis demonstrates a significant 7-month median OS benefit (34 vs 27 months) with inavolisib plus palbociclib plus fulvestrant in PIK3CA-mutated endocrine-resistant metastatic breast cancer, though the limited crossover rate (< 10%) to PIK3CA inhibitors in the control arm complicates interpretation of optimal sequencing strategies.

Paul E. Oberstein, MD; Priyadarshini Pathak, MBBS; and Tara E. Seery, MD, discuss how to optimize treatment decisions for patients with pancreatic cancer by comparing NALIRIFOX vs modified FOLFIRINOX regimens, sequencing therapies from first to second line, managing toxicities through dose modifications to maintain patients on treatment longer, and the promising pipeline of emerging targeted therapies including KRAS inhibitors and immunotherapy combinations presented at ASCO 2025.

Sandip P. Patel, MD; Zofia Piotrowska, MD, MHS; and Joel Neal, MD, PhD, discuss how the evolving landscape of EGFR-mutated non–small cell lung cancer treatment now includes 3 compelling frontline options (osimertinib monotherapy, FLAURA2 regimen, and MARIPOSA), requiring careful consideration of patient factors, disease characteristics, and toxicity profiles for optimal treatment selection and sequencing strategies.

Panelists discuss RAS mutations in pancreatic cancer, focusing on prevalence and testing, evolving second-line treatment strategies including emerging targeted agents like daraxonrasib, and key ASCO 2025 highlights and future perspectives in pancreatic ductal adenocarcinoma (PDAC).

Jason A. Mouabbi, MD, discusses how ESR1 mutations should be monitored after each progression in hormone receptor-positive breast cancer patients and treated with elacestrant, emphasizing the importance of liquid biopsies for detection and the promising results from studies like SERENA-6 that suggest switching therapy early based on molecular progression rather than waiting for radiological evidence.

Joshua Sabari, MD and Isabel Preeshagul, DO, MBS, discuss how comprehensive biomarker testing for HER2 mutations in non–small cell lung cancer (NSCLC) enables targeted treatment with emerging therapies including antibody-drug conjugates such as trastuzumab deruxtecan and promising oral tyrosine kinase inhibitors such as zongertinib and sevabertinib, which offer improved tolerability and central nervous system penetration compared with traditional chemotherapy approaches.

Panelists discuss how comprehensive biomarker testing informs patient selection for antibody-drug conjugate (ADC) therapy in HER2+ ovarian and endometrial cancers, while evaluating ADC positioning in the evolving gynecologic oncology landscape, comparing structural components that influence efficacy and safety, and outlining strategies for monitoring and managing emerging ADC toxicities.

Catherine Coombs, MD; John Allan, MD; and Joanna Rhodes, MD, MSCE, discuss how to treat patients with chronic lymphocytic leukemia (CLL) who develop high-risk disease features at relapse after initial venetoclax-based therapy. They cover treatment sequencing strategies, Bruton tyrosine kinase (BTK) inhibitor tolerability issues and switching approaches, retreatment considerations, and emerging therapies including chimeric antigen receptor (CAR) T-cell therapy and novel agents in development.

Panelists discuss the expanding treatment landscape for neuroendocrine tumors.

Panelists discuss the treatment of relapsed and refractory multiple myeloma, as well as sequencing strategies aimed at optimizing patient care and minimizing treatment-related side effects,presenting two real-world patient cases and explain our treatment approach, highlighting how they incorporate recent data into our practice.